Automated radiosynthesis of [68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617 on the iPHASE MultiSyn module for clinical applications

被引：18
作者：
Wichmann, Christian W. [1 ,2 ,3 ,4 ]
Ackermann, Uwe [1 ,3 ,4 ]
Poniger, Stan [3 ]
Young, Kenneth [3 ]
Nguyen, Benjamin [3 ]
Chan, Gordon [3 ]
Sachinidis, John [3 ]
Scott, Andrew M. [1 ,2 ,3 ,4 ]
机构：
[1] Olivia Newton John Canc Res Inst, Tumor Targeting Lab, Heidelberg, Vic 3084, Australia
[2] La Trobe Univ, Sch Canc Med, Bundoora, Vic, Australia
[3] Austin Hlth, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[4] Univ Melbourne, Dept Med, Parkville, Vic, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2021年 / 64卷 / 03期
基金：
英国医学研究理事会;
关键词：
clinical quality control; Ga‐ 68; iPHASE MultiSyn; prostate cancer; PSMA‐ 11; 617; theranostics; RESISTANT PROSTATE-CANCER; PSMA INHIBITOR; THERAPY; PET/CT;
D O I：
10.1002/jlcr.3889
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Prostate-specific membrane antigen (PSMA)-targeted imaging and therapy of prostate cancer using theranostic pairs is rapidly changing clinical practice. To facilitate clinical trials, fully automated procedures for the radiosyntheses of [Ga-68]Ga-PSMA-11 and [Lu-177]Lu-PSMA-617 were developed from commercially available precursors using the cassette based iPHASE MultiSyn module. Formulated and sterile radiopharmaceuticals were obtained in 76 +/- 3% (n = 20) and 91 +/- 4% (n = 15) radiochemical yields after 17 and 20 min, respectively. Radiochemical purity was always >95% and molar activities exceeded 792 +/- 100 and 88 +/- 6 GBq/mu mol, respectively. Quality control showed conformity with all relevant release criteria and radiopharmaceuticals were used in the clinic.
引用
收藏
页码：140 / 146
页数：7
相关论文
共 32 条
[1]   Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Kuerpig, Stefan ;
Boegemann, Martin ;
Claesener, Michael ;
Eppard, Elisabeth ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Schaefers, Michael ;
Essler, Markus .
EJNMMI RESEARCH, 2015, 5 :1-8
[2]   Continuation of comprehensive quality control of the itG 68Ge/68Ga generator and production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for clinical research studies [J].
Amor-Coarasa, Alejandro ;
Kelly, James M. ;
Gruca, Monika ;
Nikolopoulou, Anastasia ;
Vallabhajosula, Shankar ;
Babich, John W. .
NUCLEAR MEDICINE AND BIOLOGY, 2017, 53 :37-39
[3]   Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].
Benesova, Martina ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Afshar-Oromieh, Ali ;
Kratochwil, Clemens ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920
[4]  
Bögemann M, 2020, UROLOGE, V59, P680, DOI 10.1007/s00120-020-01205-w
[5]   Evaluation of an Automated Module Synthesis and a Sterile Cold Kit Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer [J].
Calderoni, Letizia ;
Farolfi, Andrea ;
Pianori, Davide ;
Maietti, Elisa ;
Cabitza, Veronica ;
Lambertini, Alessandro ;
Ricci, Giacomo ;
Telo, Silvi ;
Lodi, Filippo ;
Castellucci, Paolo ;
Fanti, Stefano .
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (05) :716-722
[6]   Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer [J].
Ceci, Francesco ;
Castellucci, Paolo ;
Fanti, Stefano .
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (01) :7-18
[7]   68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? [J].
Ceci, Francesco ;
Uprimny, Christian ;
Nilica, Bernhard ;
Geraldo, Llanos ;
Kendler, Dorota ;
Kroiss, Alexander ;
Bektic, Jasmin ;
Horninger, Wolfgang ;
Lukas, Peter ;
Decristoforo, Clemens ;
Castellucci, Paolo ;
Fanti, Stefano ;
Virgolini, Irene J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) :1284-1294
[8]   Multidose formulation of ready-to-use 177Lu-PSMA-617 in a centralized radiopharmacy set-up [J].
Chakraborty, Sudipta ;
Vimalnath, K. V. ;
Chakravarty, Rubel ;
Sarma, H. D. ;
Dash, Ashutosh .
APPLIED RADIATION AND ISOTOPES, 2018, 139 :91-97
[9]   Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent [J].
Chatalic, Kristell L. S. ;
Heskamp, Sandra ;
Konijnenberg, Mark ;
Molkenboer-Kuenen, Janneke D. M. ;
Franssen, Gerben M. ;
Clahsen-van Groningen, Marian C. ;
Schottelius, Margret ;
Wester, Hans-Juergen ;
van Weerden, Wytske M. ;
Boerman, Otto C. ;
de Jong, Marion .
THERANOSTICS, 2016, 6 (06) :849-861
[10]   Novel Preclinical and Radiopharmaceutical Aspects of [Ga-68]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer [J].
Eder, Matthias ;
Neels, Oliver ;
Mueller, Miriam ;
Bauder-Wust, Ulrike ;
Remde, Yvonne ;
Schaefer, Martin ;
Hennrich, Ute ;
Eisenhut, Michael ;
Afshar-Oromieh, Ali ;
Haberkorn, Uwe ;
Kopka, Klaus .
PHARMACEUTICALS, 2014, 7 (07) :779-796
1234